Health & Biotech

Dr Boreham’s Crucible: What the biotech minnows can learn from the $84 billion market cap CSL

February 18, 2019February 18, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: The fact Adalta’s still afloat makes it a tasty prospect

February 11, 2019February 11, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: How $18bn snore buster ResMed stacks up against ASX sleep minnows

February 4, 2019February 10, 2019 | Tim Boreham

Health & Biotech

Allegra hops closer to implanting kangaroo tendons in people

January 9, 2019February 10, 2019 | Tim Boreham

Health & Biotech

Tim Boreham: What’s next for stem cell play Regeneus as it waits for Japan deal

January 4, 2019February 10, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: More medical marijuana

December 21, 2018February 10, 2019 | Tim Boreham

Health & Biotech

Tim Boreham: Medadvisor’s nagging business model

December 17, 2018February 10, 2019 | Tim Boreham

Health & Biotech

Tim Boreham: Sperm sorter Memphasys is finding its feet as a grower, not a shower

January 10, 2019February 10, 2019 | Tim Boreham

Health & Biotech

Tim Boreham: Mach7 dishes out a version of My Health Record for the ‘ologists

December 12, 2018February 10, 2019 | Tim Boreham

Health & Biotech

Tim Boreham: Oventus Medical has put snoring to bed – now it’s time to shine and rise

December 3, 2018February 10, 2019 | Tim Boreham

Health & Biotech

Blood bank Cryosite’s cash balance is bigger than its market cap

November 5, 2018February 10, 2019 | Tim Boreham

Health & Biotech

Here’s what’s next for biotech dazzler Biotron

October 29, 2018February 10, 2019 | Tim Boreham